Recent IPO activity underscores a selective but functioning market window as of mid-October 2026, with 254 U.S. listings year-to-date and fresh filings from biotechs such as Iambic Therapeutics and City Therapeutics ahead of expected October 15-16 pricings. Persistent equity volatility, elevated Treasury yields near 19-year highs, and tempered AI valuation expectations have prompted delays or withdrawals for larger names, shifting focus to smaller, data-backed deals amid analyst caution on revenue multiples. Trader sentiment on high-profile candidates reflects these dynamics, with upcoming earnings, FOMC signals on rates, and any stabilization in growth-stock performance as key swing factors before year-end resolution.